Abstract:
Familial Mediterranean fever (FMF) is the most frequent autoinflammatory disease which can be well controlled with lifelong use of
colchicine. Daily colchicine use has been shown to reduce the frequency, severity, and duration of attacks. Colchicine also has
been found to be effective in decreasing the prevalence of amyloidosis. Therapeutic oral dose of colchicine (0.5-2.0 mg/ day) may
cause cramping, abdominal pain, hyperperistalsis, diarrhea and vomiting. Besides, colchicine may rarely cause bone marrow
failure, agranulocytosis and/ or thrombocytopenia as well. Here in we report two pediatric cases of FMF who developed
trombocytopenia after colchicine medication and call attention to colchicine related trombocytopenia.
